Press Releases

    • August 7, 2019

    Nemaura Medical Announces First Shipments of SugarBEAT® Devices to Diabetic and Pre-Diabetic Patients as Part of its First Phase of Launch

    Reports strong pre-launch consumer interest with over 17,000 potential users that have signed up to receive product information prior...

    Read more
    August 1, 2019

    Nemaura Medical Inc. Announces $8 million Senior Debt Facility Provided by Existing Investors

    Loughborough, England, Aug. 01, 2019 (GLOBE NEWSWIRE) —  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on...

    Read more
    July 18, 2019

    Nemaura Medical Inc. Appoints Chris Avery as Vice President of Global Business Operations to Support Global Commercial Launch of SugarBEAT®

    Loughborough, England , July 18, 2019 (GLOBE NEWSWIRE) —  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused...

    Read more
    July 10, 2019

    Nemaura Medical Inc. Submits De Novo 510(k) Application for SugarBEAT® to the U.S. Food and Drug Administration

    Loughborough, England , July 10, 2019 (GLOBE NEWSWIRE) —  Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused...

    Read more
    June 17, 2019

    Nemaura Provides Fiscal 2019 Year-End Business Update

    Readies launch of SugarBEAT® in United Kingdom and Germany following CE Mark approval On track to submit FDA application...

    Read more
    June 14, 2019

    Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report

    Loughborough, England, June 14, 2019 (GLOBE NEWSWIRE) —  – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused...

    Read more
    May 29, 2019

    Nemaura Announces CE Mark Approval of SugarBEAT®

    SugarBEAT® is the World’s First Non-Invasive Continuous Glucose Monitor Loughborough,England, May 29, 2019 (GLOBE NEWSWIRE) — Nemaura Medical, Inc....

    Read more
    May 2, 2019

    Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®

    Allows 3rd Party Applications to Directly access SugarBEAT® CGM Data Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) —...

    Read more
    April 23, 2019

    Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®

    Final step required prior to filing de novo application to the U.S. Food and Drug Administration Loughborough, England ,...

    Read more
    April 18, 2019

    Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT®

    Enhances Product Capabilities in Advance of CE Mark Approval April 16, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a...

    Read more